8,593 results match your criteria Annals Of Pharmacotherapy[Journal]


Intrapleural Tissue Plasminogen Activator for Traumatic Retained Hemothorax.

Ann Pharmacother 2019 Apr 21:1060028019846122. Epub 2019 Apr 21.

1 The Ohio State University Wexner Medical Center, Columbus, OH, USA.

Objective: To describe the efficacy, safety, dosing regimen, and administration technique of intrapleural alteplase for the treatment of retained hemothorax.

Data Sources: A PubMed, EMBASE, and Google Scholar search (January 2000 to February 2019) was conducted with the search terms intrapleural, fibrinolytic, fibrinolysis, alteplase, tissue plasminogen activator, and hemothorax.

Study Selection And Data Extraction: Articles were included if they described the use of intrapleural alteplase in adult patients with a retained hemothorax; single patient case reports and abstracts were excluded. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019846122DOI Listing

Epidemiology, Risk Factors, and Outcomes After Early Posttransplant Clostridiodes difficile Infection in Renal Transplant Recipients.

Ann Pharmacother 2019 Apr 21:1060028019845003. Epub 2019 Apr 21.

1 University of Wisconsin Hospital and Clinics, Madison WI, USA.

Background: Modifiable risk-factors associated with Clostridioides difficile infection (CDI) in renal-transplant (RTX) have not been clearly established and peri-transplant risk has not been described.

Objective: Evaluate epidemiology, risk-factors and outcomes after CDI occurring in the first 90 days after RTX (CDI-90).Methods: Observational cohort study/survival analysis of adult RTX recipients from 1/1/2012-12/31/2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019845003DOI Listing

Switching to Clopidogrel in Patients With Acute Coronary Syndrome Managed With Percutaneous Coronary Intervention Initially Treated With Prasugrel or Ticagrelor: Systematic Review and Meta-analysis.

Ann Pharmacother 2019 Apr 18:1060028019845334. Epub 2019 Apr 18.

3 University of Alberta, Edmonton, AB, Canada.

Objective: To evaluate the effects of switching from ticagrelor or prasugrel to clopidogrel in acute coronary syndrome (ACS) patients managed with percutaneous coronary intervention on major adverse cardiovascular events (MACEs) and bleeding.

Data Sources: We searched MEDLINE, EMBASE, CENTRAL, bibliographies of relevant articles, and clinicaltrials.gov for eligible articles published from inception to January 27, 2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019845334DOI Listing

Sound-Alike Look-Alike Confusion and Matching Medication Product Attributes: Simulated Case-Control Studies.

Ann Pharmacother 2019 Apr 18:1060028019838239. Epub 2019 Apr 18.

1 Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA.

Background: Sound-alike look-alike (SALA) medication confusions harm as many as 250 000 Americans annually. Most preventive strategies focus on medication name similarities.

Objectives: To evaluate the association between matching medication product attributes and SALA confusion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019838239DOI Listing
April 2019
1 Read

Utilization of Intra-airway Injection of Iopamidol.

Ann Pharmacother 2019 Apr 11:1060028019843652. Epub 2019 Apr 11.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019843652DOI Listing
April 2019
2.059 Impact Factor

Incidence of Acute Kidney Injury in Intermittent Versus Continuous Infusion of Polymyxin B in Hospitalized Patients.

Ann Pharmacother 2019 Apr 11:1060028019841898. Epub 2019 Apr 11.

2 Nova Southeastern University College of Pharmacy, Davie, FL, USA.

Background: Studies evaluating the risk of developing acute kidney injury (AKI) with different dosing strategies of polymyxin B are limited.

Objectives: To compare the incidence of AKI in patients treated with intermittent versus continuous polymyxin B therapy. Secondary objectives included time to onset of AKI, hospital length of stay (LOS), and all-cause hospital mortality. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1060028019841898
Publisher Site
http://dx.doi.org/10.1177/1060028019841898DOI Listing
April 2019
6 Reads

Nondihydropyridine Calcium Channel Blockers for the Treatment of Proteinuria: A Review of the Literature.

Ann Pharmacother 2019 Apr 9:1060028019843644. Epub 2019 Apr 9.

1 Auburn University Harrison School of Pharmacy, Huntsville, AL, USA.

Objective: To review the use of nondihydropyridine calcium channel blockers (non-DHP CCBs) for the treatment of proteinuria in diabetic and nondiabetic kidney disease.

Data Sources: A search using PubMed and MEDLINE, Scopus, and Google Scholar was performed from 1964 through February 2019 using the following search terms alone or in combination: verapamil, diltiazem, non-dihydropyridine calcium channel blocker, proteinuria, albuminuria, microalbuminuria, kidney disease, renal disease.

Study Selection And Data Extraction: All prospective English-language trials examining one or more non-DHP CCB for the treatment of proteinuria were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019843644DOI Listing
April 2019
5 Reads

Evaluation of Pharmacist Impact Within an Interdisciplinary Inpatient Heart Failure Consult Service.

Ann Pharmacother 2019 Apr 9:1060028019842656. Epub 2019 Apr 9.

4 Methodist University Hospital, Memphis, TN, USA.

Background: Heart failure (HF) is highly prevalent in the Veterans Affairs (VA) health care system and the leading cause of hospital discharges in the VA. Despite guideline-specific recommendations of drug therapy, many patients are not on optimal medication regimens.

Objective: To examine and quantify pharmacist impact in an interdisciplinary HF consult (IC) service on increasing use of guideline-directed medical therapy (GDMT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019842656DOI Listing

Cases of Argyria Associated With Colloidal Silver Use.

Ann Pharmacother 2019 Apr 8:1060028019844258. Epub 2019 Apr 8.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019844258DOI Listing
April 2019
1 Read

Norepinephrine and Vasopressin Compared With Norepinephrine and Epinephrine in Adults With Septic Shock.

Ann Pharmacother 2019 Apr 8:1060028019843664. Epub 2019 Apr 8.

1 Rush University Medical Center, Chicago, IL, USA.

Background: The optimal adjuvant vasopressor to norepinephrine in septic shock remains controversial.

Objective: To compare durations of shock-free survival between adjuvant vasopressin and epinephrine.

Methods: A retrospective, single-center, matched cohort study of adults with septic shock refractory to norepinephrine was conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019843664DOI Listing
April 2019
1 Read

Direct Oral Anticoagulants in Chronic Liver Disease.

Ann Pharmacother 2019 Apr 4:1060028019841582. Epub 2019 Apr 4.

3 Wingate University School of Pharmacy, Wingate, NC, USA.

Objective: To review the use of direct oral anticoagulants (DOACs) in patients with chronic liver disease (CLD).

Data Sources: A MEDLINE literature search was performed from 1964 through February 2019 using the following search terms: cirrhosis, chronic liver disease, direct oral anticoagulant, and the individual DOACs.

Study Selection And Data Extraction: All English-language human trials and reports that examined DOACs for treatment or prevention of venous thromboembolic (VTE) events in patients with CLD were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019841582DOI Listing
April 2019
3 Reads

Transition From Oral Treprostinil to Selexipag in a Patient With Pulmonary Arterial Hypertension.

Ann Pharmacother 2019 04 4:1060028019843665. Epub 2019 Apr 4.

Allegheny General Hospital, Pittsburgh, PA, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019843665DOI Listing
April 2019
1 Read

Intravenous Insulin Infusion Protocol Compared With Subcutaneous Insulin for the Management of Hyperglycemia in Critically Ill Adults.

Ann Pharmacother 2019 Mar 29:1060028019841363. Epub 2019 Mar 29.

1 North Florida/South Georgia Malcom Randall VAMC, Gainesville, FL, USA.

Background: The use of an intravenous insulin infusion protocol (IIP) is recommended for management of hyperglycemia in the intensive care unit (ICU); however, limited evidence of comparison has been made with subcutaneous (SC) insulin regimens.

Objective: This study aims to evaluate the safety and effectiveness of an IIP compared with SC insulin regimens in an ICU patient sample since the implementation of an IIP using a computerized clinical-decision support tool.

Methods: This investigation was a retrospective cohort study of patients who were treated for hyperglycemia while admitted to any of the ICUs at a Veterans Affairs Medical Center. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019841363DOI Listing

Omadacycline: A New Tetracycline Antibiotic.

Ann Pharmacother 2019 May 7;53(5):486-500. Epub 2018 Dec 7.

3 Denver Health Medical Center, Denver, CO, USA.

Objective: To review the chemistry, pharmacology, microbiology, pharmacokinetics, pharmacodynamics, clinical efficacy, tolerability, dosage, and administration of omadacycline, a new tetracycline antibiotic.

Data Sources: A literature search through PubMed, Google Scholar, and clinicaltrials.gov was conducted (2008 to October 2018) using the search terms omadacycline and PTK-0796. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028018818094DOI Listing
May 2019
1 Read

Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis.

Ann Pharmacother 2019 Mar 24:1060028019839650. Epub 2019 Mar 24.

2 Rhode Island Hospital, Providence, RI, USA.

Objective: To review the pharmacology, pharmacokinetics, safety, and efficacy of baricitinib, a recently approved selective Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA), and explore its potential role in therapy.

Data Sources: Articles were identified using a PubMed search from inception through January 2019 using the terms rheumatoid arthritis, Olumiant, baricitinib, and LY3009104, its molecular name.

Study Selection And Data Extraction: Articles relating to randomized clinical trials, pharmacology, pharmacokinetics, efficacy, and safety of baricitinib were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019839650DOI Listing
March 2019
2 Reads

Evaluation of Lactation Compatibility Reference Recommendations.

Ann Pharmacother 2019 Mar 24:1060028019839389. Epub 2019 Mar 24.

4 Avita Pharmacy, Salisbury, NC, USA.

Background: Multiple resources aid the interprofessional health care team when recommending medications for lactating patients. Varying degrees of breastfeeding compatibility and safety are recommended in different resources. New Food and Drug Administration labeling for lactation is being phased in to provide more consistent language in safety recommendations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019839389DOI Listing
March 2019
4 Reads

Payers' Perspectives on Pharmacist-Directed Care in a Community Pharmacy Setting.

Ann Pharmacother 2019 Mar 21:1060028019839440. Epub 2019 Mar 21.

1 University of Utah, Salt Lake City, UT, USA.

Background: The United States is spending an increasing share of its national income on health care while American citizens are not receiving the commensurate benefit of longer, healthier lives. Pharmacists are in a position to provide high-quality care; however, a paucity of data exists on payers' perspectives on insurance reimbursement for pharmacist-provided, community-delivered clinical services.

Objective: To understand payers' perspectives toward pharmacist-provided community-delivered advanced clinical services. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019839440DOI Listing
March 2019
2 Reads

Marijuana Use in Older Adults: Employing a Risk Reduction Strategy.

Ann Pharmacother 2019 Mar 20:1060028019838241. Epub 2019 Mar 20.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019838241DOI Listing

Impact of a Direct Oral Anticoagulant Population Management Tool on Anticoagulation Therapy Monitoring in Clinical Practice.

Ann Pharmacother 2019 Mar 10:1060028019835843. Epub 2019 Mar 10.

1 West Palm Beach VA Medical Center, FL, USA.

Background: The optimal monitoring and follow-up strategy for long-term direct oral anticoagulant (DOAC) therapy has not been established. Historically, at our medical center, DOAC patients were referred to a clinical pharmacy specialist managed anticoagulation clinic (AC) for monitoring via regularly scheduled encounters (face-to-face or telephone).

Objective: To determine if implementation of a DOAC Population Management Tool (PMT) designed to identify patients who most likely require clinical review and possibly intervention, would improve the efficacy (interventions per patient) and efficiency (time invested to generate an intervention) of monitoring over AC practices. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019835843DOI Listing
March 2019
3 Reads

No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant.

Ann Pharmacother 2019 Mar 6:1060028019836775. Epub 2019 Mar 6.

1 Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Objective: To review the literature for the treatment of classical and variant hairy cell leukemia (HCL, HCLv), evaluating efficacy, safety, and supportive care involved in the use of purine analogues (PAs), interferon, BRAF inhibitors, monoclonal antibodies, Bruton's tyrosine kinase inhibitors, and new immunotoxin, moxetumomab pasudotox-tdfk (MPT). An electronic literature search of PubMed (January 1958 to January 2019) was conducted in PubMed using the MESH terms hairy cell leukemia, hairy cell leukemia variant, cladribine, pentostatin, rituximab, interferon, vemurafenib, moxetumomab pasudotox.

Study Selection And Data Extraction: Studies written in the English language were considered for this article. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1060028019836775
Publisher Site
http://dx.doi.org/10.1177/1060028019836775DOI Listing
March 2019
9 Reads

Assessment of Condition and Medication Knowledge Gaps Among Atrial Fibrillation Patients: A Systematic Review and Meta-analysis.

Ann Pharmacother 2019 Mar 2:1060028019835845. Epub 2019 Mar 2.

1 University of British Columbia, Vancouver, BC, Canada.

Background: Patient education facilitates construction of a correct illness representation, improves beliefs about medications, and improves knowledge, factors that have been associated with better adherence.

Objective: Our objective was to characterize the published literature about atrial fibrillation (AF) patients' disease and medication knowledge to identify knowledge gaps and misconceptions to inform AF patient education strategies.

Methods: Following PRISMA guidelines, we searched PubMed, EMBASE, CINAHL, and PsychINFO from inception to May 2018 for studies that assessed AF patients' knowledge about their condition and medications. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1060028019835845
Publisher Site
http://dx.doi.org/10.1177/1060028019835845DOI Listing
March 2019
5 Reads

Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention.

Ann Pharmacother 2019 Feb 27:1060028019835166. Epub 2019 Feb 27.

2 University of Florida College of Pharmacy, Gainesville, FL, USA.

Objective: To review the pharmacology, efficacy, and safety of the calcitonin gene-related peptide (CGRP) inhibitor erenumab for migraine preventive therapy.

Data Sources: A MEDLINE/PubMed search (January 2000 to January 2019) was conducted using the keywords erenumab-aooe, erenumab, migraine, migraine prophylaxis, migraine prevention, and chronic migraine. Additional articles were identified by hand from references. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019835166DOI Listing
February 2019
13 Reads

Copanlisib: An Intravenous Phosphatidylinositol 3-Kinase (PI3K) Inhibitor for the Treatment of Relapsed Follicular Lymphoma.

Ann Pharmacother 2019 Feb 27:1060028019833992. Epub 2019 Feb 27.

1 Sylvester Comprehensive Cancer Center, Hollywood, FL, USA.

Objective: To review the mechanism of action, clinical efficacy, safety, dosage, administration, and role of copanlisib in the treatment of relapsed follicular lymphoma (FL).

Data Sources: Sources of information were identified through searches of PubMed (August 2014 to January 2019) using the key terms copanlisib, Aliqopa, PI3K inhibitor, and BAY 80-6946. Unpublished abstract information was obtained from the American Society of Clinical Oncology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019833992DOI Listing
February 2019
1 Read

Andexanet alfa: A Novel Factor Xa Inhibitor Reversal Agent.

Ann Pharmacother 2019 Feb 27:1060028019835209. Epub 2019 Feb 27.

1 University of Florida Colleges of Pharmacy and Medicine, Gainesville, FL, USA.

Objective: The purpose of this article is to review the available clinical trial data for andexanet alfa and its role in clinical practice.

Data Sources: A MEDLINE/PubMed search was conducted (January 2000 to January 2019) using the keyword andexanet alfa for clinical trials. References of identified articles were searched by hand for additional citations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019835209DOI Listing
February 2019
1 Read

Ceftaroline-Induced Thrombocytopenia: A Case Report.

Ann Pharmacother 2019 Feb 27:1060028019835208. Epub 2019 Feb 27.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019835208DOI Listing
February 2019

Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin.

Ann Pharmacother 2019 Feb 27:1060028019835202. Epub 2019 Feb 27.

2 Lexington Veterans Affairs Health Care System, Lexington, KY, USA.

Background: Lab tests such as activated partial thromboplastin time (aPTT) or anti-factor Xa (anti-Xa) levels are typically used to monitor intravenous unfractionated heparin (IV heparin), with recent evidence suggesting that anti-Xa levels may provide a more accurate measure of anticoagulation.

Objective: The Lexington Veterans Affairs Health Care System transitioned from using aPTT to anti-Xa levels in January 2017. This study was conducted to evaluate the efficacy and safety of this change. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019835202DOI Listing
February 2019

Severe Peripheral Edema in a Dabigatran-Treated Patient.

Ann Pharmacother 2019 Feb 25:1060028019834634. Epub 2019 Feb 25.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019834634DOI Listing
February 2019

Octreotide Added to a Proton Pump Inhibitor Versus a Proton Pump Inhibitor Alone in Nonvariceal Upper-Gastrointestinal Bleeds.

Ann Pharmacother 2019 Feb 25:1060028019833696. Epub 2019 Feb 25.

5 Erlanger Health System, Chattanooga, TN, USA.

Background: Literature indicating clinically relevant benefits of an adjunctive somatostatin analog to standard therapies in nonvariceal upper-gastrointestinal bleeding (NVUGIB) is lacking.

Objective: The primary objective of this study was to find the association between outcomes in patients with NVUGIB treated with octreotide and a proton pump inhibitor (PPI; combination group) compared with those treated with a PPI alone.

Methods: We conducted a retrospective cohort study of adults admitted within a 5-hospital health care system with a NVUGIB treated with a PPI continuous infusion with or without an octreotide infusion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019833696DOI Listing
February 2019
1 Read

Assessment of Late Thromboembolic Complications Post-Fontan Procedure in Relation to Different Antithrombotic Regimens: 30-Years' Follow-up Experience.

Ann Pharmacother 2019 Feb 21:1060028019829860. Epub 2019 Feb 21.

1 King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

Background: The current CHEST guidelines recommend the use of antithrombotic therapy, either aspirin or warfarin, as a primary thromboembolic complications (TECs) prophylaxis in patients who undergo Fontan procedure, without specification on drug selection or duration of therapy.

Objective: To investigate the incidence rate of late TECs, occurring after 1-year post-Fontan procedure and to assess the difference in rate of late TECs between warfarin and aspirin.

Methods: A retrospective cohort study included patients who had Fontan procedures between 1985-2010 at our institution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019829860DOI Listing
February 2019
1 Read

Managing Pharmacotherapy in People Living With HIV and Concomitant Malignancy.

Ann Pharmacother 2019 Feb 15:1060028019833038. Epub 2019 Feb 15.

4 Massachusetts College of Pharmacy and Health Sciences University, School of Pharmacy, Worcester, MA, USA.

Objective: To describe data with selected malignancies in people living with HIV (PLWH) and HIV in individuals affected by both conditions and to summarize drug-drug interactions (DDIs) with clinical recommendations for point-of-care review of combination therapies.

Data Sources: Literature searches were performed (2005 to December 2018) in MEDLINE and EMBASE to identify studies of malignancies in PLWH in the modern era.

Study Selection And Data Extraction: Article bibliographies and drug interaction databases were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019833038DOI Listing
February 2019
2 Reads

Dolutegravir-Rilpivirine, Dual Antiretroviral Therapy for the Treatment of HIV-1 Infection.

Ann Pharmacother 2019 Feb 13:1060028019831674. Epub 2019 Feb 13.

1 Auburn University Harrison School of Pharmacy, AL, USA.

Objective: To review the efficacy and safety of dolutegravir (DTG) with rilpivirine (RPV) as a dual therapy regimen in the treatment of HIV-1 infection.

Data Sources: A literature search was performed using PubMed (1966 to January 2019) and Google Scholar (2014 to January 2019) with the search terms dolutegravir, rilpivirine, dual, and switch. Other resources included review articles and the manufacturer product label. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019831674DOI Listing
February 2019
2 Reads

Intravenous Olanzapine for the Management of Agitation: Review of the Literature.

Ann Pharmacother 2019 Feb 13:1060028019831634. Epub 2019 Feb 13.

1 St John's University College of Pharmacy and Health Sciences, Queens, NY, USA.

Objective: The purpose of this review is to summarize the current evidence of the off-label use of intravenous (IV) olanzapine and discuss its risks versus benefits for the management of agitation.

Data Sources: A literature search was conducted to gather relevant data regarding IV use of olanzapine for the management of acute agitation. PubMed, EMBASE, MEDLINE, and IPA were searched using the keywords and MESH terms: olanzapine, intravenous, IV, off-label, and agitation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019831634DOI Listing
February 2019
3 Reads

Effect of an Asthma Question Prompt List and Video Intervention on Adolescents' Medication Adherence 12 Months Later.

Ann Pharmacother 2019 Feb 13:1060028019831259. Epub 2019 Feb 13.

1 University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Background: Many adolescents do not obtain the maximum benefit from their asthma medications. Improving patient-provider communication may improve adolescents' asthma knowledge, adherence, and clinical outcomes.

Objective: To determine how a question prompt list and educational video intervention affect youth- and caregiver-reported medication adherence and self-reported medication problems. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019831259DOI Listing
February 2019

Pharmacokinetics and Safety of the Integrase Inhibitors Elvitegravir and Dolutegravir in Pregnant Women With HIV.

Ann Pharmacother 2019 Feb 10:1060028019830788. Epub 2019 Feb 10.

3 University of Alberta, Edmonton, AB, Canada.

Objective: To synthesize data on the pharmacokinetics and safety of dolutegravir and elvitegravir in pregnant women living with HIV.

Data Sources: A PubMed, EMBASE, Web of Science, and Google Scholar literature search (January 2010 to December 2018) was performed using the search terms dolutegravir, elvitegravir, women, pregnant*, and HIV. Additional reports were identified from conference abstracts and review of reference lists. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019830788DOI Listing
February 2019
2 Reads

A Retrospective Analysis of the Effects of Chemotherapy-Induced Neutropenia on Overall Survival in Patients With Unresectable or Metastatic Urothelial Carcinoma to Gemcitabine Plus Cisplatin Combination Chemotherapy.

Ann Pharmacother 2019 Feb 8:1060028019830785. Epub 2019 Feb 8.

1 SEIREI Hamamatsu General Hospital, Naka-ku, Japan.

Background: Chemotherapy-induced neutropenia (CIN) is an important dose-limiting toxicity of chemotherapy. However, evidence suggests that the occurrence of CIN may be predictive of treatment outcome. Indeed, studies have revealed that the onset of CIN is associated with a good chemotherapeutic response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019830785DOI Listing
February 2019
2 Reads

Vancomycin Versus Metronidazole for Nonsevere Clostridioides difficile Infection: Are the Data Adequate to Change Practice?

Ann Pharmacother 2019 Feb 8:1060028019829764. Epub 2019 Feb 8.

1 University of Illinois at Chicago College of Pharmacy, Chicago, IL, USA.

Objective: To compare oral metronidazole and vancomycin for the treatment of mild-to-moderate Clostridioides difficile infection (mmCDI).

Data Sources: A MEDLINE literature search (inception to November 2018) was performed using the search terms metronidazole, vancomycin, and Clostridium/Clostridioides difficile. Additional references were identified from a review of literature citations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019829764DOI Listing
February 2019

Evaluating the Effect of a Patient Decision Aid for Atrial Fibrillation Stroke Prevention Therapy.

Ann Pharmacother 2019 Feb 6:1060028019828420. Epub 2019 Feb 6.

1 The University of British Columbia, Vancouver, BC, Canada.

Background: Stroke prevention therapy decisions for patients with atrial fibrillation (AF) are complex and require trade-offs, but few validated patient decision aids (PDAs) are available to facilitate shared decision making.

Objective: To evaluate the effects of a novel PDA on decision-making parameters for AF patients choosing stroke prevention therapy.

Methods: We developed an evidence-based individualized online AF PDA for stroke prevention therapy and evaluated it in a prospective observational pilot study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019828420DOI Listing
February 2019
2 Reads

Lofexidine: A Newly FDA-Approved, Nonopioid Treatment for Opioid Withdrawal.

Ann Pharmacother 2019 Feb 6:1060028019828954. Epub 2019 Feb 6.

1 Binghamton University School of Pharmacy and Pharmaceutical Sciences, NY, USA.

Objective: To review the pharmacology, efficacy, and safety of lofexidine for the treatment of opioid withdrawal secondary to the recent Food and Drug Administration (FDA) approval.

Data Sources: A literature search using PubMed was conducted (inception to December 2018) using the terms lofexidine, opioid, opiate, and withdrawal. References from retrieved articles and the prescribing information were reviewed for any additional material. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019828954DOI Listing
February 2019

The Impact of Dual Health Care System Use for Obtaining Prescription Medications on Nonadherence in Veterans With Type 2 Diabetes.

Ann Pharmacother 2019 Feb 6:1060028019828681. Epub 2019 Feb 6.

1 Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, SC, USA.

Background: Dual health system use may provide increased access to physicians, medications, and other health care resources but may also increase the complexity and coordination of medication regimens. Thus, it is important to elucidate the impact of dual use on medication adherence.

Objective: The objective of this study was to evaluate the impact on medication adherence for veterans with dual health care system use (VA and Medicare) when obtaining prescription antihyperglycemic medications to treat diabetes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019828681DOI Listing
February 2019
1 Read

Impact of Quetiapine Therapy on QTc Prolongation in Critically Ill Patients.

Ann Pharmacother 2019 Feb 1:1060028019829494. Epub 2019 Feb 1.

1 University of California San Francisco Medical Center, San Francisco, CA, USA.

Background: Quetiapine is an atypical antipsychotic commonly utilized for the management of delirium in critically ill patients. The impact of quetiapine on QTc in the critically ill population is largely unknown.

Objective: The purpose of this study was to evaluate QTc prolongation following administration of quetiapine for the management of delirium in critically ill patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019829494DOI Listing
February 2019
7 Reads

Evaluation of Rescue Thrombolysis in Cardiac Arrest Secondary to Suspected or Confirmed Pulmonary Embolism.

Ann Pharmacother 2019 Jan 30:1060028019828423. Epub 2019 Jan 30.

2 Duke University Hospital, Durham, NC, USA.

Background: Pulmonary embolism (PE) is the associated cause of unexplained cardiac arrest in 5% to 13% of patients. Although thrombolytic agents have been studied, patient outcomes during cardiac arrest are lacking.

Objective: The purpose of this study was to describe outcomes of patients who received thrombolytic therapy during cardiac arrest for suspected or confirmed PE. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019828423DOI Listing
January 2019
3 Reads

Dipeptidyl Peptidase-4 Inhibitors and Inflammatory Bowel Disease Risk: A Meta-analysis.

Ann Pharmacother 2019 Jan 30:1060028019827852. Epub 2019 Jan 30.

1 David Grant USAF Medical Center, Travis Air Force Base, CA, USA.

Background: Dipeptidyl peptidase 4 (DPP-4) inhibitors are a popular second-line treatment for type 2 diabetes mellitus. Several studies have reported on the association between DPP-4 inhibitors and the risk of developing inflammatory bowel disease (IBD), with conflicting results.

Objective: This meta-analysis aims to elucidate the risk for IBD with DPP-4 inhibitor therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019827852DOI Listing
January 2019
7 Reads

Pharmacy-Led β-Lactam Allergy Interview (BLAI) Reduces Duration of Fluoroquinolones Within a Community Hospital.

Ann Pharmacother 2019 Jan 28:1060028019826223. Epub 2019 Jan 28.

2 St Vincent's Health System, Birmingham, AL, USA.

Background: Patients with reported β-lactam allergies often receive broad-spectrum antimicrobials and have been shown to experience a variety of negative health consequences, such as increased mortality, costs, readmission, and adverse reactions. Current literature focuses on β-lactam allergy skin testing but lacks evidence on β-lactam allergy interviews (BLAI) when skin testing is unavailable.

Objective: This study aimed to test the impact of a pharmacy-led BLAI on duration of fluoroquinolones at a community hospital. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019826223DOI Listing
January 2019

Baloxavir Marboxil: The First Cap-Dependent Endonuclease Inhibitor for the Treatment of Influenza.

Authors:
Tianrui Yang

Ann Pharmacother 2019 Jan 23:1060028019826565. Epub 2019 Jan 23.

1 University of Texas at Tyler Ben and Maytee Fisch College of Pharmacy, Tyler, TX, USA.

Objective: To review the pharmacology, pharmacokinetics, clinical trials, and clinical implications of baloxavir marboxil.

Data Sources: A MEDLINE search was conducted using the terms baloxavir, baloxavir marboxil, cap-dependent endonuclease inhibitor, and polymerase acidic endonuclease inhibitor. Additional data were obtained from the prescribing information and relevant guidelines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028019826565DOI Listing
January 2019

Impact of Substance Use Disorder on the Rate of Sustained Virological Response in Veterans With Chronic Hepatitis C Treated With Direct-Acting Antivirals.

Ann Pharmacother 2019 Jan 17:1060028018824988. Epub 2019 Jan 17.

1 Durham Veterans Affairs Health Care System, Durham, NC, USA.

Background: Substance use disorders (SUDs) are commonly encountered in patients with chronic hepatitis C virus (HCV) infection. It is important to consider the impact of SUDs on HCV treatment.

Objective: To compare the rate of clinical cure (sustained virological response at least 12 weeks after end of therapy [SVR12]) in veterans with chronic HCV infection treated with direct-acting antivirals (DAAs) with and without ongoing or recent substance use. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028018824988DOI Listing
January 2019
13 Reads

Recent Evidence Examining Efficacy and Safety of Aspirin for Primary Cardiovascular Disease Prevention.

Ann Pharmacother 2019 Jan 17:1060028018825140. Epub 2019 Jan 17.

1 UIC College of Pharmacy, Rockford, IL, USA.

Background: Data on aspirin for primary prevention of cardiovascular disease (CVD) are conflicting and changing as new trials are published on the subject.

Objective: To review recent data evaluating the efficacy and safety of aspirin for primary prevention of CVD.

Data Sources: Articles evaluating aspirin for primary prevention of CVD were gathered using a MEDLINE search with the keywords aspirin review, aspirin peripheral artery disease, aspirin stroke, aspirin coronary artery disease, aspirin diabetes, aspirin primary prophylaxis, and aspirin elderly. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028018825140DOI Listing
January 2019
10 Reads

Medication Histories in Critically Ill Patients Completed by Pharmacy Personnel.

Ann Pharmacother 2019 Jan 17:1060028018825483. Epub 2019 Jan 17.

1 Duke University Hospital, Durham, NC, USA.

Background: Although critically ill adults often have extended hospital lengths of stay and are at high risk of having medication-related adverse events, the value of medication histories in these patients remains underreported.

Objective: To assess the feasibility of performing medication histories in critically ill adults and to establish the frequency of and characterize identified discrepancies.

Methods: This prospective study included patients admitted to 4 intensive care units (ICUs) in a large academic medical center and was conducted in 2 phases. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1060028018825483
Publisher Site
http://dx.doi.org/10.1177/1060028018825483DOI Listing
January 2019
17 Reads

Perioperative Bridging With Glycoprotein IIb/IIIa Inhibitors Versus Cangrelor: Balancing Efficacy and Safety.

Ann Pharmacother 2019 Jan 16:1060028018824640. Epub 2019 Jan 16.

5 University of North Carolina Medical Center, Chapel Hill, NC, USA.

Objective: To review the efficacy and safety of perioperative administration of intravenous (IV) antiplatelet agents as a substitute for oral P2Y inhibitors and to provide clinicians guidance on optimal and cost-effective use of these medications.

Data Sources: A MEDLINE literature search (1950 to November 2018) was performed using the key search terms abciximab, bridging, cangrelor, cardiac surgery, coronary artery bypass surgery, eptifibatide, intravenous antiplatelet agent, and tirofiban. Additional references were identified from a review of literature citations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028018824640DOI Listing
January 2019
2 Reads

Brigatinib: Novel ALK Inhibitor for Non-Small-Cell Lung Cancer.

Ann Pharmacother 2019 Jan 13:1060028018824578. Epub 2019 Jan 13.

1 State University of New York, Binghamton, NY, USA.

Objective: We review here the pharmacology, pharmacokinetics, efficacy, safety, dosage and administration, potential drug-drug interactions and place in therapy of brigatinib for abnormal anaplastic lymphoma kinase (ALK) specific non-small-cell lung cancer (NSCLC).

Data Sources: A literature search using PubMed was conducted using the terms brigatinib and ALK positive NSCLC from January 2013 to November 2018.

Study Selection And Data Extraction: All English-language articles evaluating brigatinib were analyzed for this review. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1060028018824578DOI Listing
January 2019
1 Read